January 1, 1993Circulation
Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Why the study?
Does active smoking affect mortality in patients receiving thrombolytic therapy for acute myocardial infarction?
Population
8,259 patients receiving thrombolytic therapy for acute myocardial infarction
Comparison
Active smoking vs Nonsmoking (never smoked) or ex-smoking
Design
Cohort
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Nonsmoking linked to higher adjusted mortality in thrombolysis-treated AMI; hypothesis-generating for unmeasured factors in the smoker's paradox.
Structured PICO
Does active smoking affect mortality in patients receiving thrombolytic therapy for acute myocardial infarction?
P
Population
8,259 patients receiving thrombolytic therapy for acute myocardial infarction (2,366 nonsmokers, 2,244 ex-smokers, and 3,649 active smokers)
I
Intervention
Active smoking
C
Comparator
Nonsmoking (never smoked) or ex-smoking
O
Outcome
Mortality during hospitalization and 6 months afterwardhard clinical
Smokers receiving thrombolytic therapy for acute myocardial infarction have lower in-hospital and 6-month mortality compared to nonsmokers, a paradox largely explained by their younger age and fewer comorbidities at presentation.
Limitations
- Retrospective analysis
Cite This Study
Barbash et al. (1993) studied this question.